Gastrointestinal transport processes: Potentials for stereoselectivities at substrate-specific and nonspecific epithelial transport systems

Chemical Analysis

Volumn 142, Issue , 1997, Pages 611-632

  Langguth, Peter ^a   Amidon, Gordon L ^b   Lipka, Elke ^c   Spahn Langguth, Hildegard ^d  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TSRL INC   (United States)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347171858     PISSN: 00692883     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (61)

1. Ader, P., Langguth, P., and Spahn-Langguth, H. (1997). Stereoselective uptake of baclofen enantiomers in the gut: Studies with the rat everted-sac model. Arch. Pharm. (Weinheim) (submitted).
2. Amidon, G., Lennernäs, H., Shah, V. P., and Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413-420.
3. Anderle, P., Niederer, E., Spahn-Langguth, H., Merkle, H. P., and Langguth, P. (1996). Expression of bioavailability-limiting ATP-dependent efflux pump in intestinal epithelium. Naunyn Schmiedeberg's Arch. Pharmacol., 353 (Suppl.), R153.
4. Bergström, R. F., Kay, D. R., and Wagner, J. G. (1981). The pharmacokinetics of penicillamine in a female mongrel dog. J. Pharmacokinet. Biopharm., 9, 603-621.
5. Bohner, V., Rutishauser, B., Pernard, J. C., Ottinger, C., Wunderli-Allenspach, H., Merkle, H. P., and Langguth, P. (1995). Proc. Intern. Symp. Control Release Bioact. Mater., p. 540, Seattle.
6. Duddu, S. P., Vakilynejad, M., Jamali, F. and Grant, D. J. (1993). Stereoselective dissolution of propranolol hydrochloride from hydroxypropyl methylcellulose matrices. Pharm. Res., 10, 1648-1653.
7. Endicott, J. A. and Ling, V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171.
8. Fassihi, A. R. (1993). Racemates and enantiomers in drug development. Int. J. Pharm., 92, 1-14.
9. Funaki, T., Furuta, S., and Kaneniwa, N. (1986). Discontinuous absorption property of cimetidine. Int. J. Pharm., 31, 119-123.
10. Gottesman, M. M. (1993). How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res., 53, 747-754.
11. Gottesman, M. M. and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem., 62, 385-427.
12. Gramatté, T. (1995). Small intestinal secretion of the β-blocker talinolol: Direct demonstration is possible by perfusion studies in man. Naunyn Schmiedeberg's Arch. Pharmacol., 351 (Suppl.), R1.
13. Hampson, D. R., Baker, G. B., and Coutts, R. T. (1986). A comparison of the neurochemical properies of the stereoisomers of tranylcypromine in the central nervous system. Cell. Mol. Biol., 32, 593-599.
14. Hartmann, C., Frölich, M., Krauss, D., Spahn, H., Knauf, H., Mutschler, E. (1990). Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with renal insufficiency. Eur. J. Clin. Pharmacol., 38, 587-593.
15. Hendel, J. and Brodthagen, H. (1984). Enterohepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker. Eur. J. Clin. Pharmacol., 26, 103-107.
16. Hunter, J., Jepson, M. A., Tsuruos, T., Simmons, N. L., and Hirst, B. H. (1993). Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem., 268, 14991-14997.
17. Jamali, F., Mehvar, R., and Pasutto, F. M. (1989). Enantioselective aspects of drug action and disposition. J. Pharm. Sci., 78, 695-715.
18. Karlsson, J., Kuo, S. M., and Artursson, P. (1993). Transport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotein. Biochem. Pharmacol., 110, 1009-1016.
19. Klaassen, C. D. (1988). Intestinal and hepatobiliary disposition of drugs. Toxicol. Pathol., 16, 130-137.
20. Kuo, S. M., Whitby, B. R., Artursson, P., and Ziemniak, J. A. (1994). The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. Pharm. Res., 11, 648-653.
21. Langguth, P., Khan, P. J., and Garrett, E. R. (1990). Pharmacokinetics of morphine and its surrogates XI: Effect of simultaneously administered naltrexone and morphine on the pharmacokinetics and pharmacodynamics of each in the dog. Biopharm. Drug Dispos., 11, 419-444.
22. Langguth, P., Lee, K. M., Spahn-Langguth, H., and Amidon, G. L. (1994). Variable gastric emptying and discontinuities in drug absorption profiles: Dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharm. Drug Dispos., 15, 719-746.
23. Langguth, P., Möhrke, W., Möhler, H., and Spahn-Langguth, H. (1997). Drug absorption via intestinal vs. nasal mucosae: Dependence of rate and extent of systemic availability of tranylcypromine enantiomers upon the application site. Biopharm. Drug Dispos. (submitted for publication).
24. 14C-polyethylene glycol (PEG) 4000. Pharm. Res., 10, 130-135.
25. Lennernäs, H. and Regardh, C. G. (1993b). Dose-dependent intestinal absorption and significant intestinal secretion (exsorption) of the beta-blocker pafenolol in the rat. Pharm. Res., 10, 727-731.
26. Lennernäs, H. and Regardh, C. G. (1993a). Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double-peaks in the plasma concentration-time profile. Pharm. Res., 10, 879-883.
27. Lien, E. J., Rodriguez de Miranda, J. F., and Ariens, E. J. (1982). Quantitative structure-activity correlation of optical isomers: A molecular basis for Pfeiffer's rule. Mol. Pharmacol., 12, 598-604.
28. Lipka, E., Lee, I. D., Langguth, P., Spahn-Langguth, H., Mutschler, E., and Amidon, G. L. (1995). Celiprolol double peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs. J. Pharmacokin. Biopharm., 23, 267-286.
29. Lipka, E., Spahn-Langguth, H., Mutschler, E., and Amidon, G. L. (1996). The non-linear intestinal permeability and pharmacokinetics of celiprolol in conscious dogs: Evidence for in-vivo intestinal secretion. Eur. J. Pharm. Sci. (submitted for publication).
30. Meijer, D. K. F. and van der Sluijs, P. (1989). Covalent and noncovalent protein binding of drugs: Implications for hepatic clearance, storage, and cell-specific drug delivery. Pharm. Res., 6, 105-118.
31. Merfeld, A. E., Mlodozeniec, A. R., Cortese, M. A., Rhodes, J. B., Dressman, J. B., and Amidon, G. L. (1986). The effect of pH and concentration on α-methyldopa absorption in man. J. Pharm. Pharmacol., 38, 815-822.
32. Merino, M., Peris-Ribera, J. E., Torres-Molina, F., and Sanchez-Pico, A. (1989). Evidence of a specialized transport mechanism for the intestinal absorption of baclofen. Biopharm. Drug Dispos.. 10, 279-297.
33. Oberle, R. L. and Amidon, G. L. (1987). The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine, an explanation for the double peak phenomenon. J. Pharmacokin. Biopharm., 15, 529-544.
34. Olpe, H. R., Baudry, M., Fagni, L., and Lynch, G. (1982). The blocking action of baclofen on excitatory transmission in the rat hippocampal slice. J. Neurosci., 2, 698-703.
35. Ott, R. J. and Giacomini, K. M. (1993). Stereoselective transport of drugs across epithelia. In Wainer I.W. (ed.), Drug Stereochemistry, New York: Marcel Dekker, pp. 281-314.
36. Oude Elferink, R. P., Meijer, D. K., Kuipers, F., Jansen, R L., Groen, A. K., and Groothuis, G. M. (1995). Hepatobiliary secretion of organic compounds: Molecular mechanisms of membrane transport. Biophys. Acta, 1241, 215-268.
37. Pfeiffer, C. C. (1956). Optical isomerism and pharmacological action, a generalization. Science, 124, 29-31.
38. Plumb, J. A., Milroy, R., Kaye, S. B. (1990). The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem. Pharmacol., 39, 787-792.
39. 1-adrenoceptor antagonist with atypical absorption and disposition properties - in man. Pharm. Res., 7, 1222-1227.
40. Rowland, M. and Tozer, T. N. (1989). Clinical Pharmacokinetics: Concepts and Applications, 2nd Edition, Lea & Febiger, Philadelphia, P.A., pp. 148-173.
41. Schneider, E., Gleiter, C., Schug, B., Hermann, R., Gundert-Remy, U., Elze, M., and Blume, H. (1996). Influence of food intake on the bioavailability of α-lipoic acid. Naunyn Schmiedeberg's Arch. Pharmacol., 353 (Suppl.), R153.
42. Sezaki, H. and Kimura, T. (1983). Carrier-mediated transport in drug absorption. In D. D. Breimer and P. Speiser (eds.), Topics in Pharmaceutical Sciences. Amsterdam: Elsevier, 133-142.
43. Soldner, A., Spahn-Langguth, H., Voith, B., Stapff, M. and Mutschler, E. (1996). Losartan and EXP 3174 in rats: Concentrations in central and peripheral compartments as basis for PK/PD correlations, (submitted for publication.)
44. Spahn-Langguth, H., Langguth, P., and Brockmeier, D. (1993). The pharmacokinetics of piretanide in humans: An update. In S. Johnson and F. N. Johnson (eds.), The Diuretic Agents 2: Piretanide. Carnforth, UK: Marius Press, 11-29.
45. Spahn-Langguth, H., Hahn, G., Mutschler, E., Elze, M., Potthast, H., Blume, H., and Möhrke, W. (1994). Determination of the bioavailability of tranylcypromine with a stereospecific assay. Eur. J. Pharm. Sci., 2, 160.
46. Spahn-Langguth, H., Möhrke, W. and Langguth, P. (1994). Variabilities in input profiles of tranylcypromine enantiomers following p.o.-administration. Eur. J. Pharm. Sci., 2, 160.
47. Stahl, E. (1993). Stereochemische Aspekte der Pharmakokinetik der lipophilen β-Adrenozeptor-Antagonisten Carvedilol und Propranolol" Ph.D. thesis, Department of Pharmacy, Johann Wolfgang Goethe-University, Frankfurt/Main.
48. Stahl, E., Baumgartner, U., Henke, D., Schölmerich, J., Mutschler, E., and Spahn-Langguth, H. (1993). Rats with portocaval shunt as a potential pharmacokinetic model for liver cirrhosis. Chirality, 5, 120-125.
49. Taylor, M. D. and Amidon, G. L. (eds.) (1995). Peptide-based drug design: Controlling transport and metabolism. Washington. DC: ACS.
50. Thiebault, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. (1987). Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84, 7735-7738.
51. Tsuji, A. (1995). Intestinal absorption of β-lactam antibiotics. In M. D. Taylor and G. L. Amidon (eds.), (1995). Peptide-Based Drug Design: Controlling Transport and Metabolism. Washington, DC: ACS, pp. 101-134.
52. Tsuji, A. and Tamai, I. (1996). Carrier-mediated intestinal transport of drugs. Pharm. Res., 13, 963-977.
53. Wacher, V. J., Wu, C. Y., and Benet, L. Z. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 13, 120-134.
54. Wade, D. N., Mearrick, P. T., and Morris, J. L. (1977). Active transport of L-dopa in the intestine. Nature (London), 242, 463-465.
55. Weber-Grandke, H., Hahn, G., Mutschler, E., Möhrke, W., Langguth, P., and Spahn-Langguth, H. (1993). The pharmacokinetics of tranycypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers. Br. J. Clin. Pharmacol., 36, 363-365.
56. Wetterich, U., Spahn-Langguth, H., Rösch, W., Mutschler, E., Terhaag, B., and Langguth, P. (1996). Evidence for intestinal secretion as additional clearance pathway of talinolol enantiomers. Pharm. Res., 13, 526-534.
57. Yee, S. and Amidon, G. L. (1995). Oral absorption of angiotensin-converting enzyme inhibitors and peptide prodrugs. In M. D. Taylor, G. L. Amidon (eds.), Peptide-based drug design: Controlling transport and metabolism. Washington, DC: ACS, pp. 135-147.
58. Yoshikawa, T., Muranishi, N., Yoshida, M., Oguma, T., Hirano, K., and Yamada, H. (1989). Transport characteristics of ceftibuten (7432-S), a new oral cepham, in rat intestinal brush-border membrane vesicles: Proton-coupled and stereoselective transport of ceftibuten. Pharm. Res., 6, 302-307.
59. Yuasa, H., Amidon, G. L., and Fleisher, D. L. (1993). Peptide carrier-mediated transport in intestinal brush border membrane vesicles of rats and rabbits: Cephradine uptake and inhibition. Pharm. Res., 10, 400-404.
60. Yuasa, H., Fleisher, D. L., and Amidon, G. L. (1994). Noncompetitive inhibition of cephradine uptake by enalapril in rabbit intestinal brush-border membrane vesicles: An enalapril specific inhibitory binding site on the peptide carrier. J. Pharmacol. Exp. Ther., 269, 1107-1111.
61. Yun, C. H., Lee, H. S., Rho, J. K., Jeong, H. G., and Guengerich, F. P. (1995). Oxidation of the angiotensin-II receptor antagonist losartan (DuP 755) in human liver microsomes. Role of cytochrome P4503A in formation of the active metabolite EXP 3174. Drug Metab. Dispos., 23, 285-289.